First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up.

While the PFS benefit with tislelizumab plus chemotherapy was more pronounced in the ITT population of the current study (HR: 0.60 [95% CI 0.50–0.72]) [ 11 ], the JAS also showed a trend toward improvement (HR: 0.80 [95% CI 0.47–1.36]), with smaller sample size (N = 66) likely contributing to the wider CI.

also in 53,322 other papers